Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RYTM | US
-1.38
-2.71%
Healthcare
Biotechnology
30/06/2024
04/10/2024
49.63
49.00
50.06
49.00
Rhythm Pharmaceuticals Inc. a commercial-stage biopharmaceutical company focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC) proprotein convertase subtilisin/kexin type 1 leptin receptor (LEPR) deficiency obesity and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities steroid receptor coactivator 1 deficiency obesity SH2B1 deficiency obesity MC4 receptor deficiency obesity and other MC4R disorders. The company was formerly known as Rhythm Metabolic Inc. and changed its name to Rhythm Pharmaceuticals Inc. in October 2015. Rhythm Pharmaceuticals Inc. was founded in 2008 and is headquartered in Boston Massachusetts.
View LessStrong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
31.9%1 month
40.3%3 months
47.8%6 months
49.5%-
-
79.79
6.42
0.66
-12.65
29.12
-
-263.94M
3.03B
3.03B
-
-139.21
-
51.30
-143.42
25.32
23.16
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
5.55
Range1M
10.64
Range3M
15.18
Rel. volume
0.50
Price X volume
11.72M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Dynegy Inc | DYN | Biotechnology | 32.58 | 3.27B | -8.35% | n/a | 3.32% |
Iovance Biotherapeutics Inc | IOVA | Biotechnology | 10.46 | 3.17B | 7.17% | n/a | 10.63% |
Amicus Therapeutics Inc | FOLD | Biotechnology | 10.6 | 3.14B | 0.09% | n/a | 335.08% |
Xenon Pharmaceuticals Inc | XENE | Biotechnology | 40.73 | 3.09B | -0.27% | n/a | 1.19% |
Kymera Therapeutics Inc | KYMR | Biotechnology | 43.06 | 2.83B | -4.31% | n/a | 12.87% |
PTC Therapeutics Inc | PTCT | Biotechnology | 35.1 | 2.70B | -3.65% | n/a | -40.35% |
Edgewise Therapeutics Inc. | EWTX | Biotechnology | 28.4 | 2.66B | 4.18% | n/a | 0.98% |
Zai Lab Limited | ZLAB | Biotechnology | 26.36 | 2.63B | 2.93% | n/a | 11.88% |
Protagonist Therapeutics Inc | PTGX | Biotechnology | 44.37 | 2.61B | -1.36% | 16.38 | 2.03% |
Geron Corporation | GERN | Biotechnology | 4.32 | 2.60B | -2.70% | n/a | 28.38% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -12.65 | 0.76 | Cheaper |
Ent. to Revenue | 29.12 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 79.79 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 47.80 | 74.67 | Lower Risk |
Debt to Equity | 6.42 | -1.82 | Expensive |
Debt to Assets | 0.66 | 0.26 | Expensive |
Market Cap | 3.03B | 3.73B | Par |